Beam Therapeutics Valuation Multiples

Beam Therapeutics Overview

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Founded

2017

HQ

Employees

511

Website

beamtx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $112M

EBITDA: ($399M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Beam Therapeutics Financials

Beam Therapeutics reported last 12-month revenue of $112M and negative EBITDA of ($399M).

In the same LTM period, Beam Therapeutics generated $112M in gross profit, ($399M) in EBITDA losses, and had net loss of ($200M).

Beam Therapeutics P&L

In the most recent fiscal year, Beam Therapeutics reported revenue of $140M and EBITDA of ($361M).

Beam Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Beam Therapeutics Stock Performance

Beam Therapeutics has current market cap of $3B, and enterprise value of $2B.

Beam Therapeutics' stock price is $31.39.

Beam Therapeutics Valuation Multiples

Beam Therapeutics trades at 18.9x EV/Revenue multiple, and (5.3x) EV/EBITDA.

Beam Therapeutics Financial Valuation Multiples

As of April 18, 2026, Beam Therapeutics has market cap of $3B and EV of $2B.

Equity research analysts estimate Beam Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Beam Therapeutics has a P/E ratio of (16.0x).

Beam Therapeutics Margins & Growth Rates

Beam Therapeutics' revenue in the last 12 month declined by (56%).

Beam Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.0M for the same period.

Beam Therapeutics' rule of 40 is (1140%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Beam Therapeutics' rule of X is (1242%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Beam Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Beam Therapeutics M&A Activity

Beam Therapeutics acquired XXX companies to date.

Last acquisition by Beam Therapeutics was on XXXXXXXX, XXXXX. Beam Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Beam Therapeutics Investment Activity

Beam Therapeutics invested in XXX companies to date.

Beam Therapeutics made its latest investment on XXXXXXXX, XXXXX. Beam Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).